Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.21 USD
Change Today -0.22 / -1.34%
Volume 332.3K
NXTM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

nxstage medical inc (NXTM) Snapshot

Open
$16.44
Previous Close
$16.43
Day High
$16.55
Day Low
$16.17
52 Week High
04/27/15 - $19.63
52 Week Low
09/16/14 - $11.50
Market Cap
1.0B
Average Volume 10 Days
352.7K
EPS TTM
$-0.40
Shares Outstanding
63.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NXSTAGE MEDICAL INC (NXTM)

Related News

No related news articles were found.

nxstage medical inc (NXTM) Related Businessweek News

No Related Businessweek News Found

nxstage medical inc (NXTM) Details

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Its primary product includes the System One, a portable hemodialysis system used for the treatment of acute and chronic kidney failure, and fluid overload. The company operates in three segments: System One, In-Center, and Services. The System One segment engages in the sale and rental of the NxStage System One and PureFlow SL dialysate preparation equipment, and sale of disposable products in the home and critical care markets. The home market focuses on the treatment of end-stage renal disease (ESRD) patients in the home or a home-like setting, and critical care market on the treatment of hospital-based patients with acute kidney failure or fluid overload. The In-Center segment sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers; and needles for apheresis. The Services segment provides dialysis services to patients at NxStage Kidney Care dialysis centers. NxStage Medical, Inc. markets its products through direct sales and distributors to hospitals and dialysis centers in the United States and internationally. The company, formerly known as QB Medical, Inc., was founded in 1998 and is headquartered in Lawrence, Massachusetts.

3,400 Employees
Last Reported Date: 02/26/15
Founded in 1998

nxstage medical inc (NXTM) Top Compensated Officers

Founder, Chief Executive Officer and Director
Total Annual Compensation: $496.9K
President
Total Annual Compensation: $338.6K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $305.6K
President of Nxstage Kidney Care
Total Annual Compensation: $306.4K
Senior Vice President of Quality Assurance, R...
Total Annual Compensation: $350.0K
Compensation as of Fiscal Year 2014.

nxstage medical inc (NXTM) Key Developments

Nxstage Medical, Inc. Presents at Marcum Microcap Conference 2015, May-27-2015

Nxstage Medical, Inc. Presents at Marcum Microcap Conference 2015, May-27-2015 . Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States.

NxStage Medical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter of 2015

NxStage Medical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $79,482,000 against $72,221,000 for the same period a year ago. Loss from operations was $5,579,000 against $4,789,000 for the same period a year ago. Net loss before income taxes was $5,556,000 against $4,964,000 for the same period a year ago. Net loss attributable to stockholders of the company was $5,658,000 or $0.09 per basic and diluted share against $5,275,000 or $0.09 per basic and diluted share for the same period a year ago. Net cash provided by operating activities was $416,000 against net cash used in operating activities of $3,380,000 for the same period a year ago. For the 2015 second quarter, the company expects revenue to be between $79.0 million and $80.5 million, and a net loss in the range of $5.5 million to $7.0 million. As the company expects to work towards sustainable operating profit in the products business, the company expects the majority of the company's projected net loss to be related to its investment in NxStage Kidney Care.

NxStage Medical, Inc. Establishes New Scientific Advisory Board

NxStage Medical, Inc. announced the Company's new Chronic Scientific Advisory Board, an esteemed group of thought leaders focused on evaluating and advancing home dialysis therapies. Senior Medical Advisor, Dr. Allan J. Collins, will lead the distinguished board of nephrologists and cardio renal experts in actively defining, developing and conducting strategic data analyses that promote the efficacy, safety, and benefits of home hemodialysis (HHD) therapy with the NxStage System One. Board members and affiliations include: Allan Collins, MD - Senior Medical Advisor of NxStage Medical, Inc., Chris Chan, MD – University Health Network, Toronto, Canada, Michael A. Kraus, MD – Indiana University School of Medicine, Clarian Health, Peter McCullough, MD – Baylor University Medical Center, Jose Morfin, MD – UC Davis School of Medicine, John Burkart, MD – Wake Forest University Medical Center, Mike Copland, MD – University of British Columbia, Vancouver General Hospital, Richard Fluck, MD – Royal Derby Hospital, Derby, United Kingdom, Sheru Kansal, MD – Cleveland Clinic, Paul Komenda, MD – Seven Oaks General Hospital, Winnipeg, Canada, and George Bakris, MD - University of Chicago Medicine. This new panel will continue to build the body of evidence to advance adoption of therapy with the NxStage System One. Through their findings, the board will seek to highlight the benefits of HHD therapy and advance the quality of dialysis care. The group will also advise NxStage on other focus items in its innovation pipeline, specifically with new perspectives related to peritoneal dialysis and alternative treatment applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NXTM:US $16.21 USD -0.22

NXTM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $16.05 USD -0.10
ICU Medical Inc $97.00 USD -0.18
Merit Medical Systems Inc $20.56 USD +0.06
Orthofix International NV $32.77 USD -0.33
RTI Surgical Inc $6.47 USD +0.16
View Industry Companies
 

Industry Analysis

NXTM

Industry Average

Valuation NXTM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.3x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NXSTAGE MEDICAL INC, please visit www.nxstage.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.